Lactobacillus salivarius AP-32 and Lactobacillus reuteri GL-104 decrease glycemic levels and attenuate diabetes-mediated liver and kidney injury in db/db mice.
Pei-Shan HsiehHsieh-Hsun HoShih-Hung HsiehYi-Wei KuoHsiu-Ying TsengHui-Fang KaoJiu-Yao WangPublished in: BMJ open diabetes research & care (2021)
Our data elucidate a novel role for probiotics in glycemic regulation in the host. L. salivarius AP-32 and L. reuteri GL-104 directly reduce monosaccharide transporter expression in gut cells and have potential as therapeutic probiotics for patients with T2DM.
Keyphrases
- type diabetes
- glycemic control
- induced apoptosis
- transcription factor
- poor prognosis
- cardiovascular disease
- cell cycle arrest
- electronic health record
- endoplasmic reticulum stress
- big data
- oxidative stress
- insulin resistance
- binding protein
- skeletal muscle
- long non coding rna
- artificial intelligence
- machine learning
- metabolic syndrome
- wild type
- deep learning
- climate change
- data analysis